Cara Therapeutics Inc (CARA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Christopher Posner
Employees:
80
4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR, STAMFORD, CT 06902
203-406-3700

Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)

Data derived from most recent annual or quarterly report
Market Cap 183.407 Million Shares Outstanding53.943 Million Avg 30-day Volume 674.927 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.56
Price to Revenue6.117 Debt to Equity0.0 EBITDA-85.7 Million
Price to Book Value1.9364 Operating Margin-201.82690000000002 Enterprise Value140.747 Million
Current Ratio8.554 EPS Growth0.128 Quick Ratio7.246
1 Yr BETA 1.1542 52-week High/Low 12.98 / 3.24 Profit Margin-195.1575
Operating Cash Flow Growth-41.8995 Altman Z-Score3.49 Free Cash Flow to Firm -79.377 Million
Earnings Report2023-08-07
View SEC Filings from CARA instead.

View recent insider trading info

Cara Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CARA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CARA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-04-06 by TERRILLION SCOTT
  • 4: filed on 2023-04-06 by GONCALVES JOANA
  • 4: filed on 2023-04-06 by MENZAGHI FREDERIQUE PH.D.
  • 4: filed on 2023-03-07 by POSNER CHRISTOPHER
  • 4: filed on 2023-03-07 by MENZAGHI FREDERIQUE PH.D.
  • 4: filed on 2023-03-07 by TERRILLION SCOTT
  • 4: filed on 2023-03-07 by GONCALVES JOANA
  • 4: filed on 2023-03-03 by TERRILLION SCOTT
  • 4: filed on 2023-03-03 by MAYNARD RYAN D
  • 4: filed on 2023-03-03 by GONCALVES JOANA

    • Events (8k)

  • 8-K: filed on 2023-03-23:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-03-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    11.6 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    POSNER CHRISTOPHER PRESIDENT AND CEO

    • Officer
    • Director
    		 172,514 2023-05-05 5

    MENZAGHI FREDERIQUE PH.D. CHIEF SCIENTIFIC OFF,SVP-R&D

    • Officer
    		 156,740 2023-04-04 4

    TERRILLION SCOTT SEC'Y; CHIEF COMPLIANCE & G.C.

    • Officer
    		 91,046 2023-04-04 4

    GONCALVES JOANA CHIEF MEDICAL OFFICER

    • Officer
    		 56,404 2023-04-04 7

    MAYNARD RYAN D CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-01 3

    VON MOLTKE LISA

    • Director
    		 45,841 2023-01-02 2

    VOGELBAUM MARTIN

    • Director
    		 44,988 2022-09-14 2

    BAINS HARRISON M JR

    • Director
    		 25,076 2022-07-15 2

    IVES JEFFREY L.

    • Director
    		 15,476 2022-07-15 2

    MAKARA RICHARD VP, HEAD OF ACCTING;CONTROLLER

    • Officer
    		 13,583 2022-06-15 2

    SHIFF SUSAN PH.D.

    • Director
    		 36,072 2022-06-02 1

    REILLY THOMAS CHARLES CHIEF FINANCIAL OFFICER

    • Officer
    		 37,811 2022-03-03 0

    VIFOR (INTERNATIONAL) LTD

    VIFOR PHARMA LTD.

    VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.

    • 10% Owner
    		 7,396,770 2021-10-20 0

    CHALMERS DEREK T PRESIDENT & CEO

    • Officer
    • Director
    		 991,405 2021-09-07 0

    MOHINDRU MANI CFO & CHIEF STRATEGY OFFICER

    • Officer
    		 17,441 2019-12-02 0

    STAUFFER JOSEPH WILLIAM CHIEF MEDICAL OFFICER

    • Officer
    		 2,000 2018-10-17 0

    SCHOELL JOSEF CHIEF FINANCIAL OFFICER

    • Officer
    		 50,000 2017-07-26 0

    SLAGEL DEAN

    • Director
    		 1,064,338 2017-06-29 0

    RHO VENTURES VI LP

    RMV VI, L.L.C.

    RHO CAPITAL PARTNERS LLC

    LESCHLY MARK

    KAIROUZ HABIB

    RUCH JOSHUA

    • 10% Owner
    		 3,568,057 2017-03-31 0

    LEWIS MICHAEL E CHIEF SCIENTIFIC ADVISOR

    • Officer
    		 0 2017-03-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    POSNER CHRISTOPHER - Director - Officer PRESIDENT AND CEO

    		2023-05-09 16:22:31 -0400 2023-05-05 S 3,869 $4.40 d 172,514 direct yes -2.8916 1.0843 7.2289 5 -3.6145 3

    MENZAGHI FREDERIQUE PH.D. - Officer CHIEF SCIENTIFIC OFF,SVP-R&D

    		2023-04-06 17:12:46 -0400 2023-04-04 S 2,733 $4.91 d 156,740 direct yes -3.2538 -3.9046 -19.5228 0.0 1 -19.5228 31

    TERRILLION SCOTT - Officer SEC'Y; CHIEF COMPLIANCE & G.C.

    		2023-04-06 17:14:33 -0400 2023-04-04 S 2,481 $4.91 d 91,046 direct yes -3.2538 -3.9046 -19.5228 0.0 1 -19.5228 31

    GONCALVES JOANA - Officer CHIEF MEDICAL OFFICER

    		2023-04-06 17:13:41 -0400 2023-04-04 S 2,481 $4.91 d 56,404 direct yes -3.2538 -3.9046 -19.5228 0.0 1 -19.5228 31

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CARA THERAPEUTICS INC CARA 2023-05-29 22:15:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 21:45:05 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 21:15:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 20:45:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 20:15:05 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 19:45:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 19:15:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 18:45:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 18:15:03 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 17:45:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 17:15:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 16:45:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 16:15:03 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 15:45:03 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 15:15:03 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 14:45:05 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 14:15:04 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 13:45:05 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 13:15:03 UTC 4.6709 0.3991 650000
    CARA THERAPEUTICS INC CARA 2023-05-29 12:45:03 UTC 4.6709 0.3991 650000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund CARA -258.0 shares, $-3408.18 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund CARA -70.0 shares, $-924.7 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund CARA -326.0 shares, $-4306.46 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund CARA -2979.0 shares, $-34794.72 2023-01-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments